PTK2 and thyroid gland carcinoma: Combined treatment with PLX4720 and dasatinib inhibits MAPK and SRC signaling and attenuates the PLX4720-induced augmentation of FAK and AKT phosphorylation in a subset of thyroid cancer cell lines